quinazolines has been researched along with Minimal Disease, Residual in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T | 1 |
| Alladin, A; Burwinkel, B; Garcia, M; Gibson, TJ; Havas, KM; Jechlinger, M; Kafkia, E; Klaus, B; Milchevskaya, V; Patil, KR; Pruneri, G; Radic, K; Rotmensz, N; Schneeweiss, A; Sotillo, R; Stolte, J | 1 |
| Bastida, CC; Falchook, GS; Kurzrock, R; Lippman, SM | 1 |
| Funakoshi, Y; Maeda, H; Takeuchi, Y | 1 |
| Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Gaballah, K; Hills, A; Oakley, R; Partridge, M; Ryan, A | 1 |
| Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K | 1 |
| Hashimoto, K; Hayashi, Y; Horinouchi, H; Izumi, Y; Kohno, M; Nomori, H; Ohtsuka, T | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K | 1 |
1 review(s) available for quinazolines and Minimal Disease, Residual
| Article | Year |
|---|---|
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
2 trial(s) available for quinazolines and Minimal Disease, Residual
| Article | Year |
|---|---|
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2021 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
8 other study(ies) available for quinazolines and Minimal Disease, Residual
| Article | Year |
|---|---|
Metabolic shifts in residual breast cancer drive tumor recurrence.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lipid Metabolism; Metabolic Networks and Pathways; Mice; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxidative Stress; Progesterone; Quinazolines; Reactive Oxygen Species; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm, Residual; Quinazolines; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab; Vascular Endothelial Growth Factor A | 2014 |
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines | 2016 |
The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Neoplasm, Residual; Neoplasms, Experimental; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm, Residual; Quinazolines; Salvage Therapy | 2012 |
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Quinazolines | 2007 |